Lineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $2.27 million versus the consensus estimate of $510 thousand.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.